The global Chronic Obstructive Pulmonary Disease (COPD) market size is expected to be valued at US$ 21.58 Billion in 2023. With the increasing alcohol consumption among people, the overall demand for Chronic Obstructive Pulmonary Disease (COPD) is projected to grow at a CAGR of 4.4% between 2023 and 2033, totaling around US$ 33.19 Billion by 2033.
| Data Points | Key Statistics |
|---|---|
| Chronic Obstructive Pulmonary Disease (COPD) Market Value 2023 | US$ 21.58 Billion |
| Chronic Obstructive Pulmonary Disease (COPD) Market Projected Value (2033) | US$ 33.19 Billion |
| Chronic Obstructive Pulmonary Disease (COPD) Market CAGR (2023 to 2033) | 4.4% |
According to the analysis of Future Market Insights, the Chronic Obstructive Pulmonary Disease (COPD) market is expected to fuel over the analysis period, attributed to an increase in patient population, due to a substantial rise in incidence as well as the prevalence of asthma.
As per a 2021 factsheet from the World Health Organization (WHO), asthma is a major non-communicable disease (NCD), affecting both children as well as adults. Globally, it affected an estimated 262 million people in 2019 and caused 461,000 deaths.
Enormous investments in the study of asthma drugs, accompanied by strategic collaborations such as mergers and acquisitions are the business strategies followed by the major companies in the market. Hence, the aforementioned factors are anticipated to boost the growth of the COPD market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for Chronic Obstructive Pulmonary Disease (COPD) is projected to increase at a CAGR of 4.4% during the forecast period between 2023 and 2033, reaching a total of US$ 33.19 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.4%.
According to Future Market Insights, a market research and competitive intelligence provider, the Chronic Obstructive Pulmonary Disease (COPD) market was valued at US$ 20.67 Billion in 2022.
As per a March 2021 study by José Luis Izquierdo et al., published in the European Respiratory Journal, allergy-related factors such as eczema and rhinitis were less common in asthmatic patients with COVID-19. Though, there was a high prevalence of these comorbidities observed in patients with COVID-19, who required hospital admission.
The continual rise in the geriatric population worldwide is a major factor driving market growth. As the World Ageing 2020 report, in 2020, there were around 727 million people aged 65 years or more in the world. In addition, the number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 9.3% in 2020 to reach 16% by 2050. Thus, the growing geriatric population is likely to fuel the market growth during the analysis period, owing to the fact that asthma is a widely prevalent disease found in people over the age of 65.
Moreover, technological advancements are another major factor that is projected to create lucrative avenues for market growth. Also, limitations of traditional treatments, such as the late onset of action as well as low efficacy, are anticipated to encourage the development of novel targeted drugs, which in turn are propelling market growth.
Awareness Efforts by Individual Organizations to Fuel the Market Growth
As per a 2019 study published by the National Center for Biotechnology Information, globally, 212.3 million prevalent cases of chronic obstructive pulmonary disease (COPD) were reported, with COPD accounting for 3.3 million deaths and 74.4 million disability-adjusted life years. In addition, as per the American Lung Association, in 2018, 9.0 million adults, or 3.6% of those aged 18 or older, had chronic bronchitis. In 2018, 16.4 million people, or 6.6% of adults, reported a diagnosis of any type of COPD (chronic bronchitis, emphysema, or COPD). Hence, the rise in the incidence of chronic obstructive pulmonary disease is anticipated to augment the market growth in the near future.
Additionally, in November 2021, as per the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote a better understanding of COPD, a progressive lung disease that affects millions across the US. Further, rising awareness among the people, regarding chronic obstructive pulmonary disease (COPD) and its symptoms is important as early diagnosis, as well as treatment can improve quality of life.
Rise in Adoption of More Effective Combination Therapy to Accelerate the Market Growth
The combination therapies include LABA-ICS, triple therapy, LAMA-ICS, and other combination drugs. The adoption of combination therapy is surging, as it is more effective than the separate use of bronchodilators and corticosteroids. Moreover, a rise in the number of patients successfully treated with combination therapy, who were not showing signs of recovery with bronchodilators or corticosteroid treatments is a major factor that is projected to accelerate the global chronic obstructive pulmonary disease market in the forthcoming years. Also, combination therapy is considered to be more effective than monotherapy for improving symptoms as well as the quality of life.
Principal Consultant
The Side Effects of COPD Drugs to Restrain the Market Growth
The side effect of the drugs used in treating chronic obstructive pulmonary disease is one of the major factors hindering the growth of the COPD market during the analysis period. For instance, as per the data published by the National Center for Biotechnology Information, there are some serve side effects associated with the drugs that are used in the treatment of chronic obstructive pulmonary disease, namely oral infections, bruising, and hoarseness.
Moreover, these medications are useful for people with frequent exacerbations of Chronic Obstructive Pulmonary Disease. An instance of inhaled steroids includes Fluticasone (Flovent HFA). Also, respiratory infections are observed in people with COPD, who are more likely to catch flu, colds, and pneumonia. Chronic Obstructive Pulmonary Disease can cause many complications like depression, heart problems, high blood pressure in lung arteries, and lung cancer in some cases.
Challenges of New Drug Development to Limit the Market Growth
Drug failures (termination) in clinical trials as well as the development of new drugs are challenging tasks that are anticipated to impede the growth of the COPD market in the near future. For instance, in May 2019, benralizumab, an asthma drug failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD.
Additionally, the Phase III, randomized, placebo-controlled, double-blind, parallel-group clinical trials TERRANOVA and GALATHEA evaluated the efficacy and safety of benralizumab, for the prevention of exacerbations in patients with moderate to very severe COPD.
Well-Structured Healthcare Industry in the Region to Fuel the Market Growth
The Chronic Obstructive Pulmonary Disease (COPD) Market in North America is expected to accumulate the highest market share of 44% in 2023.
The regional market growth is attributed to the factors such as the availability of well-defined reimbursement policies from private and public health insurance firms, and the highly structured healthcare industry in the region. Moreover, the presence of a large number of players in North America, coupled with an increase in research & development activities to provide advanced and efficient products, are other factors boosting the growth of the COPD market in the region.
As per the Lung Association, COPD is prevalent in men and women and is the sixth most common factor of hospitalization in women and fourth most in men in Canada. The market is also driven by factors including the rapid pace of industrialization, exponentially increasing air pollution, and the adoption of a sedentary lifestyle in the region. Also, lack of awareness of COPD, and the increasing smoking population are other factors that are likely to escalate the regional market growth during the forecast period. The region is expected to hold the highest CAGR of 4.3% during the forecast period.
Increase in Geriatric Population in the Region to Fuel the Market Growth
The Chronic Obstructive Pulmonary Disease (COPD) Market in Asia Pacific is expected to accumulate the second-highest market share of 43% in 2023.
Asia Pacific has a relatively untapped chronic obstructive pulmonary disease treatment market, compared to the developed regions such as North America and Europe. Therefore, the region offers lucrative opportunities to COPD market players. Factors such as a surge in the geriatric population, high incidence of chronic obstructive pulmonary disease, and rise in patient population are expected to fuel the COPD market in the region.
Furthermore, the Asia Pacific COPD market is largely driven by the rising prevalence of respiratory distress conditions. For instance, as per the data published by the World Health Organization (WHO), due to COPD, more than 90% of deaths occur in low and middle-income countries. Rapid urbanization that causes an increase in air pollution provides amplifies the predisposition to acquire respiratory diseases like COPD, thus creating significant avenues for the COPD drugs market in the region. Asia Pacific is expected to hold the highest CAGR of 4.2% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Combination Therapy Segment to beat Competition in Untiring Market
On the basis of drug class, the global Chronic Obstructive Pulmonary Disease (COPD) market is dominated by the Combination Therapy Segment, which accounts for a share of 45%. The segment is expected to hold a CAGR of 4.3% over the analysis period.
The segment is expected to dominate the global market over the analysis period, attributed to the increase in the efficacy of combination therapy in COPD treatment. In addition, an increase in the success rate of combination therapy in COPD treatment, and recent regulatory approvals are anticipated to propel the adoption of combination therapy.
Chronic Bronchitis Segment to Drive the Chronic Obstructive Pulmonary Disease (COPD) Market
Based on the Type, the chronic bronchitis segment is expected to witness a significant growth of 43% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.2% CAGR over the analysis period.
The segment’s growth is attributed to the factors such as the fact that chronic bronchitis is a group of lung diseases that causes airflow blockage and breathing issues. It is widespread among smokers and rising at a rapid pace. Hence, an upsurge in breathing issues among smokers, coupled with a rise in airflow blockage is a major factor fueling the segment’s growth during the forecast period.
Retail Pharmacies Segment to Drive the Chronic Obstructive Pulmonary Disease (COPD) Market
Based on the Distribution Channel, the retail pharmacies segment is expected to witness a significant growth of 42% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.2% CAGR over the analysis period.
The segment is expected to grow at a rapid pace in the forthcoming years, owing to the factors such as an increase in the number of retail pharmacies in developing countries, as well as an increase in the number of COPD therapeutics dispensed through retail pharmacies.
Chronic Obstructive Pulmonary Disease (COPD) Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base. For instance,
Prominent players in the Chronic Obstructive Pulmonary Disease (COPD) market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals, among others.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4.4% from 2023 to 2033 |
| Market Value in 2023 | US$ 21.58 Billion |
| Market Value in 2033 | US$ 33.19 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
As of 2022, the market for Chronic Obstructive Pulmonary Disease (COPD) was valued at US$ 20.67 Billion, as per FMI
By 2023-end, sales of Chronic Obstructive Pulmonary Disease (COPD) closed at a value of US$ 21.58 Billion
From 2018 to 2022, Chronic Obstructive Pulmonary Disease (COPD) demand expanded at a CAGR of 2.4%
From 2023 to 2033, Chronic Obstructive Pulmonary Disease (COPD) sales are expected to flourish at a CAGR of 4.4%
By 2033, the market value of Chronic Obstructive Pulmonary Disease (COPD) is expected to reach US$ 33.19 Billion.
By Type, the Chronic Bronchitis segment constitutes the bulk of the market share of 43% in 2022.
By Distribution Channel, the Retail Pharmacies segment dominates the market with a share of 42% in 2022.
1. Executive Summary | Chronic Obstructive Pulmonary Disease (COPD) Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By COPD Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Billion) Analysis By COPD Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By COPD Type, 2023 to 2033 5.3.1. Emphysema 5.3.2. Chronic Bronchitis 5.4. Y-o-Y Growth Trend Analysis By COPD Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By COPD Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Billion) Analysis By Treatment Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Treatment Type, 2023 to 2033 6.3.1. Drugs 6.3.2. Surgery 6.3.3. Oxygen Therapy 6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Billion) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals & Clinics 7.3.2. Home Care Settings 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The US 9.2.1.2. Canada 9.2.2. By COPD Type 9.2.3. By Treatment Type 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By COPD Type 9.3.3. By Treatment Type 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By COPD Type 10.2.3. By Treatment Type 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By COPD Type 10.3.3. By Treatment Type 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. The UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By COPD Type 11.2.3. By Treatment Type 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By COPD Type 11.3.3. By Treatment Type 11.3.4. By End User 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By COPD Type 12.2.3. By Treatment Type 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By COPD Type 12.3.3. By Treatment Type 12.3.4. By End User 12.4. Key Takeaways 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By COPD Type 13.2.3. By Treatment Type 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By COPD Type 13.3.3. By Treatment Type 13.3.4. By End User 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. U.S. 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By COPD Type 14.1.2.2. By Treatment Type 14.1.2.3. By End User 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By COPD Type 14.2.2.2. By Treatment Type 14.2.2.3. By End User 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By COPD Type 14.3.2.2. By Treatment Type 14.3.2.3. By End User 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By COPD Type 14.4.2.2. By Treatment Type 14.4.2.3. By End User 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By COPD Type 14.5.2.2. By Treatment Type 14.5.2.3. By End User 14.6. The UK. 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By COPD Type 14.6.2.2. By Treatment Type 14.6.2.3. By End User 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By COPD Type 14.7.2.2. By Treatment Type 14.7.2.3. By End User 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By COPD Type 14.8.2.2. By Treatment Type 14.8.2.3. By End User 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By COPD Type 14.9.2.2. By Treatment Type 14.9.2.3. By End User 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By COPD Type 14.10.2.2. By Treatment Type 14.10.2.3. By End User 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By COPD Type 14.11.2.2. By Treatment Type 14.11.2.3. By End User 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By COPD Type 14.12.2.2. By Treatment Type 14.12.2.3. By End User 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By COPD Type 14.13.2.2. By Treatment Type 14.13.2.3. By End User 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By COPD Type 14.14.2.2. By Treatment Type 14.14.2.3. By End User 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By COPD Type 14.15.2.2. By Treatment Type 14.15.2.3. By End User 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By COPD Type 14.16.2.2. By Treatment Type 14.16.2.3. By End User 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By COPD Type 14.17.2.2. By Treatment Type 14.17.2.3. By End User 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By COPD Type 14.18.2.2. By Treatment Type 14.18.2.3. By End User 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By COPD Type 14.19.2.2. By Treatment Type 14.19.2.3. By End User 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By COPD Type 14.20.2.2. By Treatment Type 14.20.2.3. By End User 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By COPD Type 15.3.3. By Treatment Type 15.3.4. By End User 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Abbott 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. AstraZeneca 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Dr. Reddy’s Laboratories Ltd 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. F. Hoffmann-La Roche Ltd 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. GSK 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Merck 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Novartis AG 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Pfizer Inc 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. GlaxoSmithKline 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Chiesi Farmaceutici S.p.A 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 16.1.11. Boehringer Ingelheim Pharmaceuticals 16.1.11.1. Overview 16.1.11.2. Product Portfolio 16.1.11.3. Profitability by Market Segments 16.1.11.4. Sales Footprint 16.1.11.5. Strategy Overview 16.1.11.5.1. Marketing Strategy 16.1.12. Sunovion Pharmaceuticals 16.1.12.1. Overview 16.1.12.2. Product Portfolio 16.1.12.3. Profitability by Market Segments 16.1.12.4. Sales Footprint 16.1.12.5. Strategy Overview 16.1.12.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Chronic Obstructive Pulmonary Disease (COPD) Market
